About Affimed Therapeutics
Affimed Therapeutics is a clinical stage biotech company developing unique proprietary antibody formats, so called TandAbs®, as novel treatments for life threatening diseases. The company has been generating a pipeline of preclinical and clinical candidates based on its TandAb® technology platform.
Affimed´s lead AFM13 is in clinical phase I studies for the treatment of Hodgkin Lymphoma. Orphan Drug Designation has been granted both in the US and in Europe. AFM11 to treat Non-Hodgkin Lymphoma and AFM15 to treat autoimmune diseases are currently in preclinical development. Further novel candidates are being developed for the treatment of solid tumors, asthma and autoimmune diseases.
TandAbs® are tetravalent bispecific antibody formats. They possess the same avidity for each target as an IgG and represent a unique and superior alternative to first generation antibody formats/scaffolds due to their longer half-life allowing convenient dosing schemes. In addition, TandAbs® have an excellent safety profile due to the lack of an Fc-portion. Robust production and downstream processing for TandAbs® have been established. Finally, TandAb® molecules display excellent product stability, making TandAbs® a potent alternative to monoclonal antibodies. TandAbs® can act as recruiting machinery for immune effector cells such as T-cells or NK-cells (RECRUIT-TandAb®), or via the dual inhibition of two targets such as signaling pathways (BiBLOCK-TandAb®). PROLONG-TandAbs® for the further optimization of pharmacokinetic properties are in development and complete Affimed´s TandAb® technology platform.
The company has raised €20 million in a Series C financing in 2010 led by Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed, resulting in a total of €58 million venture capital since its foundation in 2000 as a spin-off from the German Cancer Research Centre (DKFZ) in Heidelberg. Affimed has 30 employees and works together with several consultants and product development companies. The company enjoys a strong IP situation for major world markets including EU, USA and Japan.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice